港股異動丨貝康醫療-B(2170.HK)上市首日大漲15.31% 每手浮盈2095港元
格隆匯2月8日丨貝康醫療-B(2170.HK)上市首日高開近10%,現漲幅擴大至15.31%,報31.55港元,總市值84億港元。不計手續費,每手浮盈2095港元。公司是輔助生殖基因檢測解決方案的創新平台,2018年、2019年收益分別為3260.9萬、5568.5萬元人民幣。此次上市全球發售6666.7萬股,其中香港發售3333.5萬股,國際發售3333.2萬股,每手500股,香港公開發售獲402.8倍認購,一手中籤率10%,淨籌17.167億港元。清池資本等多家基石投資者已合共認購2550.25萬股,相當於緊隨全球發售完成後公司已發行股本的約9.6%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.